Abstract:More than 20% Chinese patients with IBD develop thiopurine-induced leucopoenia. Recent retrospective studies have confirmed that NUDT15 R139C variant is a reliable marker of thiopurine-induced leucopoenia in Asian population. Thus we conduct this prospective study to explore whether an optimising strategy based on NUDT15 R139C genotypes affect outcomes of Chinese patients with Crohn’s disease (CD). A prospective, randomised study was conducted in two tertiary hospitals in China (NCT02929706). CD patients (18–65 years old) with indication of the use of thiopurine were included. The exclusion criteria were: Contraindication of thiopurine, previous use of azathiopurine and co-treatment with 5-ASA or allopurinol. The Patients were randomly assigned to the intervention group (pre-genotyping NUDT 15 R139C) or control group (receive standard dosage of azathiopurine with a target dosage of 2–2.5 mg/kg/day). Patients in the intervention group found to be wild-type carriers were prescribed with standard dose of azathiopurine, while the heterozygotes received 50% of the standard dosage. Considering all the variant of homozygotes develop leucopoenia in the previous study, these patients in the intervention group did not receive thiopurine. NUDT15 R139C genotypes were determined with PCR-RFLP and sequencing. Patients were followed for 48 weeks. The primary endpoint was the differences of incidence of leucopoenia (white blood cell <3500 mm−3).The secondary outcomes were other adverse events and the efficacy (evaluated by CDAI, CRP, and mucosal healing) between the two optimisation strategies. A total of 400 Chinese CD patients were randomised. The frequency of NUDT15 R139C variant, sex, age, baseline CDAI were similar in the two groups. The rate of thiopurine-induced leucopoenia is significantly lower in the intervention group (20.8% vs. 29.7%; p = 0.041; relative risk = 0.619; 95% confidence interval (0.389–0.982).The difference is more significant in patients with NUDT15 variant [29.6 vs. 65.7 (RR 0.220, 95% CI 0.07–0.65)]. The patients develop leucopoenia in the intervention group seems milder the control group (Grade 1; 68.6% vs. 45.8%, p = 0.04). No differences of other adverse events were found. We compare the efficacy in patients treated with corticosteroids and maintain remission with AZA only. One hundred and twenty-one patients were included and no differences were found in CDAI, CRP level, and the rate of mucosal healing at the 48th week. Pre-genotyping NUDT15 R139C before starting thiopurine could be a promising strategy to reduce the rate of leucopoenia. This optimisation strategy does not seem to influence the clinical efficacy in 48 weeks of follow-up.

TT Genotype of Rs10036748 in TNIP 1 Shows Better Response to Methotrexate in a Chinese Population: a Prospective Cohort Study

MTHFR Gene Polymorphism Association With Psoriatic Arthritis Risk and the Efficacy and Hepatotoxicity of Methotrexate in Psoriasis

Anti-TNF- Αtreatment-Related Pathways and Biomarkers Revealed by Transcriptome Analysis in Chinese Psoriasis Patients

Genome-wide association analysis of anti-TNF-α treatment response in Chinese patients with psoriasis

Influence of C677T Polymorphism of 5,10-Methylenetetrahydrofolate Reductase on Methotrexate Toxicity

Lack of Association Between TESPA1 Gene Polymorphisms (rs1801876, rs2171497, rs4758994, and rs997173) and Ankylosing Spondylitis in a Chinese Population

Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients

Thiopurine methyltransferase gene polymorphisms and activity in Chinese patients with inflammatory bowel disease treated with azathioprine.

Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial

Genetic Susceptibility to Ulcerative Colitis in the Chinese Han Ethnic Population: Association with Tnf Polymorphisms

Thiopurine Methyltransferase Gene Polymorphisms in Chinese Patients with Inflammatory Bowel Disease

Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome

Impact of TYMS gene polymorphism on the outcome of methotrexate treatment in a sample of Iraqi rheumatoid arthritis patients – identification of novel single nucleotide polymorphism: Cross-sectional study

Association of rs610604 in TNFAIP3 and rs17728338 in TNIP1 gene polymorphisms with psoriasis susceptibility: a meta-analysis of case-control studies

P469 Effectiveness of Dose Optimisation by Pre-Genotyping NUDT 15 R139C on Reducing Thiopurine-Induced Leucopoenia in Chinese Patients with Crohn’s Disease: a Randomised Controlled Trial

Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis

Germline genetic variations in methotrexate pathway are associated with pharmacokinetics, outcome, and toxicity in patients with primary central nervous system lymphoma

Preliminary study for predicting better methotrexate efficacy in Japanese patients with rheumatoid arthritis

NLRP3 (rs10754558) gene polymorphism and tumor necrosis factor alpha as predictors for disease activity and response to methotrexate and adalimumab in psoriasis

Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients

The Association between Genetics and Response to Treatment with Biologics in Patients with Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, and Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis